title: Clinical trials in cellular immunotherapy for brain/CNS tumors.
abstract: High-grade gliomas are the most common type of primary malignant brain/CNS tumor. There have been only modest advances in surgical techniques, radiotherapy and chemotherapy for high-grade gliomas over the past several decades. None of these have provided a major improvement in survival for patients. Recently, immunotherapy has been explored for the treatment of high-grade gliomas. Immunotherapy capitalizes on the specificity of the host immune system to selectively target tumor cells for destruction, while sparing normal brain parenchyma, thus making it a particularly attractive option. This article provides a comprehensive review of published clinical trials evaluating cellular immunotherapy in primary brain/CNS tumors.
authors.affiliation: Michael G DeGroote School of Medicine, McMaster University, 1280 Main Street W, Hamilton, ON, L8S 4K1, Canada.
authors.forename: Jetan
authors.initials: J
authors.lastname: Badhiwala
authors.forename: William K
authors.initials: WK
authors.lastname: Decker
authors.forename: Michael E
authors.initials: ME
authors.lastname: Berens
authors.forename: Ratan D
authors.initials: RD
authors.lastname: Bhardwaj
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D016543:Central Nervous System Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*